Crucell to Buy SBL Vaccin

Crucell < ?XML:NAMESPACE PREFIX = ST1 />NV has agreed to buy Swedish biotech company SBL Vaccin AB for Euro 39.4 million in cash from 3i Group and SEB. The deal is expected to close on Thursday. www.crucell.com www.sblvaccines.se